This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Accession Therapeutics LTD

Profile

Creating the ideal oncotherapy: a universal cancer bispecific platform How do you deal with tumor diversity to kill all tumor cells? Tumours are very heterogenous, so it is difficult to identify a single tumour selective antigen that could be used to target all tumour cells and achieve a high proportion of complete responses. Accession has developed a first-of-its-kind universal bispecific that targets all tumor cells, including tumor stroma, recruiting and activating a potent immune response. However, a universal bispecific must only be expressed in the tumor to avoid systemic toxicity. Accession has a unique viral expression system (Trocept), the first of its kind engineered NOT to infect healthy tissue, that can be administered intravenously and only infect cancer cells. Trocept enables the universal bispecific to be only expressed in, and secreted from, tumor cells. This technology solves the main limitation of other viral therapies that infect normal cells (particularly the liver) rapidly removing other viral therapies from the circulation BEFORE it can reach the tumor. Accession believes that this novel tumor disrupting immunotherapy could lead to a step change to cancer treatment for patients with solid tumors.